Stephen Curtis is responsible for assessing potential life science investments and supporting emerging portfolio companies for 2M Companies, the Dallas-based family office of Morton H. Meyerson. Prior to joining 2M, Steve led cross-functional efforts to identify, evaluate, and in-license novel biopharmaceutical technologies across a wide range of therapeutic areas for Reata Pharmaceuticals. Before relocating to Dallas, Steve completed his PhD in biological and biomedical sciences at Harvard Medical School in Boston. His doctoral studies focused on the cellular biology of lung cancer development, propagation, and progression. Steve graduated summa cum laude from Cornell University, earning a dual BS degree in molecular biology and applied economics and management.